Welcome to Dailypedia

Results of a study financed by Johnson & Johnson Inc.'s Ortho-McNeil Neurologics, makers of the migraine medication Topamax, suggest that the drug may also be effective in the treatment of alcohol addiction. The study followed 371 heavy drinkers for 14 weeks. By the end of the study, 15% of the participants taking the drug had quit drinking for at least 7 weeks. Only 3% in the placebo group had done the same. Topamax works by inhibiting dopamine, a neurotransmitter commonly associated with the brain's pleasure system, and appears to curb the craving for alcohol.